Inymel Biomedica S.L. 

Inymel (IMB) is a clinical-stage biotech company developing first-in-class melatonin treatments.

OWNER

Francisco Lopez Luque (See Profile)


Sector

Biotech

Stage

Development, market readiness, clinical trial

Country

Spain


We have discover the fundamental role of injectable melatonin to treat infectious diseases (IP owned).

Our trial proves Melatonin is useful against sepsis, which occurs in all severe Covid 19 patients

Melatonin is 1 of the 16 PREDICTIVE repurposable drugs against Human CoVs

Inymel is discussing with the AEMPS about a clinical trial applying melatonin injection to patients COVID19

This information is confidential, do not share or copy.

You can visit their website or

Download the Pitch Deck
Other files:

Therapeutic Algorithm for Use of Melatonin in Patients With COVID-19 - Frontiers in Medicine

Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2 - Nature

COVID-19: Melatonin as a potential adjuvant treatment - ScienceDirect

Description section of Inymel Patent

Under evaluation at least till: 7th June

If you want to have more information or you want to review the project, you have to login or register

KEEP REVIEWING

©2023 BioExpert Network

About cookies

This website uses cookies to give you the best user experience. If you continue browsing you are giving your consent for the acceptance of those cookies and the acceptance of our cookies policy.

If you continue to browse and use this website you are agreeing to comply with and be bound by the following Terms of Use

ACEPTAR
Aviso de cookies

Log in with your credentials

or    

Forgot your details?

Create Account

Skip to toolbar